When VWF Cannot Protect Factor VIII
When VWF Cannot Protect Factor VIII
Delivery and delayed postpartum hemorrhage in type 2N von Willebrand disease
By William C. Aird, MD
Case Presentation
A 23-year-old woman with type 2N von Willebrand disease (VWD) presents at 26 weeks of pregnancy with vaginal bleeding.
She was diagnosed during childhood after heavy bleeding and excessive bleeding following a dental procedure. Since diagnosis, she has received VWF-containing concentrate before invasive procedures.
Her family history is negative for diagnosed bleeding disorders.
Laboratory testing shows:
| Test | Result |
|---|---|
| Hemoglobin | 12.0 g/dL |
| Platelet count | 242 × 10⁹/L |
| VWF activity | 106% |
| Factor VIII activity | 17% |
The vaginal bleeding diminishes, and immediate delivery is not required.
The striking laboratory feature is the markedly reduced factor VIII level despite preserved VWF activity.
Which laboratory pattern most strongly suggests type 2N VWD?
Explanation
Type 2N VWD is caused by impaired binding of VWF to factor VIII. VWF may be present in normal amounts and may retain normal platelet-dependent activity, but it cannot adequately protect factor VIII from clearance.
The characteristic laboratory clue is therefore factor VIII that is disproportionately low relative to VWF antigen and activity.
Underlying Biology
VWF has two major hemostatic roles.
It mediates platelet adhesion at sites of vascular injury, and it serves as the carrier protein for factor VIII.
In type 2N VWD, variants in the VWF gene impair the ability of VWF to bind factor VIII. Factor VIII is synthesized, but without effective binding to VWF it is removed rapidly from the circulation.
The resulting phenotype may resemble mild or moderate hemophilia A.
The distinction matters:
| Disorder | Primary defect |
|---|---|
| Hemophilia A | Reduced or dysfunctional factor VIII caused by an F8 variant |
| Type 2N VWD | Impaired binding and stabilization of factor VIII caused by a VWF variant |
Type 2N VWD is generally inherited in an autosomal recessive pattern, whereas hemophilia A is X-linked.
Why is factor VIII activity reduced in type 2N VWD?
Explanation
VWF protects factor VIII from premature clearance. When VWF cannot bind factor VIII effectively, factor VIII remains vulnerable to rapid removal from plasma.
The central problem is therefore reduced survival, not failure of synthesis.
The Desmopressin Question
Earlier in pregnancy, the patient underwent a desmopressin trial.
Before treatment, factor VIII activity was below 5%. Immediately after desmopressin, it rose to 102%.
No later factor VIII levels were obtained.
The immediate response appeared impressive, but its duration was unknown.
This distinction is especially important in type 2N VWD. Desmopressin can release endogenous VWF and factor VIII, but the released VWF still has impaired factor VIII-binding capacity. Factor VIII may rise sharply and then fall rapidly.
Why was the immediate increase in factor VIII after desmopressin insufficient to establish that desmopressin would provide reliable peripartum protection?
Explanation
A desmopressin trial should assess both magnitude and durability.
An immediate rise demonstrates that factor VIII and VWF can be released from storage sites. It does not show that factor VIII will remain elevated long enough to cover labor, delivery, neuraxial anesthesia, or postpartum bleeding risk.
In type 2N VWD, the underlying binding defect may lead to rapid loss of the initial response.
Recurrent Bleeding and Planned Delivery
At 29 weeks, the patient returns with vaginal bleeding and contractions. Her cervix is dilating, and vaginal delivery is anticipated.
Repeat testing shows:
| Date | VWF activity | Factor VIII |
|---|---|---|
| March 16 | 106% | 17% |
| April 2 | 120% | 9% |
| April 3 | Not limiting | 40% |
Despite preserved VWF activity, factor VIII remains substantially reduced.
Because labor is progressing and neuraxial anesthesia is being considered, the hematology team recommends Humate-P.
The product is dosed to provide approximately 50 IU of factor VIII per kilogram, with a goal factor VIII level near 100% at delivery.
After the first dose:
| Time | Factor VIII |
|---|---|
| Before Humate-P | 40% |
| After Humate-P | 138% |
A second dose is given the following day. Factor VIII subsequently rises to 331%.
The patient delivers a baby girl vaginally without major bleeding.
Why was a concentrate containing both VWF and factor VIII particularly appropriate in this patient?
Explanation
This patient had two linked needs.
She required factor VIII immediately to achieve a safe hemostatic level, and she required functional donor VWF capable of binding and protecting factor VIII after infusion.
A VWF–factor VIII concentrate addresses both needs.
Monitoring After Delivery
The postpartum plan is to maintain factor VIII above 50% for 48 to 72 hours.
Serial factor VIII levels show:
| Postpartum interval | Factor VIII |
|---|---|
| Immediately after additional Humate-P | 331% |
| Postpartum day 1 | 238% |
| Postpartum day 2 | 191% |
| Postpartum day 3 | 176% |
Because levels remain well above target without further concentrate, testing is stopped and she is discharged.
This apparent stability is reassuring, but it does not eliminate later postpartum risk.
Delayed Postpartum Hemorrhage
Twelve days after delivery, the patient is readmitted with heavy vaginal bleeding.
She reports saturating approximately 10 pads in 24 hours.
At presentation:
| Test | Result |
|---|---|
| Factor VIII activity | 57% |
| Hemodynamic status | Stable |
| Main bleeding site | Vaginal |
The bleeding begins to improve after admission, but it remains clinically significant.
She receives tranexamic acid and Humate-P, dosed to raise factor VIII toward 100%. Factor VIII levels are monitored while active bleeding continues.
Obstetric evaluation proceeds in parallel because delayed postpartum hemorrhage may also result from retained products, infection, subinvolution, or other anatomic causes.
Which statement best explains why delayed postpartum hemorrhage can occur despite successful factor coverage at delivery?
Explanation
Peridelivery replacement corrects the immediate deficiency but does not remove the inherited defect.
As infused factor and VWF decline, the patient again depends on endogenous VWF that binds factor VIII poorly. At the same time, pregnancy-associated elevations in VWF and factor VIII begin to recede, and the placental implantation site remains a large healing vascular surface.
The result is a period of renewed vulnerability to bleeding.
What is the most appropriate approach to active delayed postpartum bleeding in a patient with type 2N VWD?
Explanation
Delayed postpartum hemorrhage in a patient with VWD is both an obstetric and hemostatic problem.
Management may require:
- assessment for retained products, uterine atony, subinvolution, or infection
- tranexamic acid
- VWF-containing concentrate or another appropriate factor strategy
- serial factor VIII monitoring during active bleeding
- red-cell support when clinically indicated
The bleeding disorder modifies the response to the obstetric lesion; it does not make the lesion irrelevant.
What Each Result Tells Us
| Finding | Diagnostic or clinical meaning |
|---|---|
| Preserved VWF activity with very low factor VIII | Suggests impaired VWF–factor VIII binding |
| Immediate response to desmopressin | Stored VWF and factor VIII can be released |
| No delayed level after desmopressin | Duration of response remains unknown |
| Large rise after Humate-P | Replacement supplies factor VIII and functional carrier VWF |
| Sustained factor VIII elevation for several days | Strong immediate recovery and stabilization |
| Delayed postpartum bleeding | Initial peridelivery correction does not eliminate later risk |
| Factor VIII of 57% during active bleeding | Numerically above a minimal threshold, but not necessarily adequate for the clinical situation |
Teaching Points
- Type 2N VWD should be suspected when factor VIII is disproportionately low relative to VWF antigen and platelet-dependent VWF activity.
- The central defect is impaired VWF binding to factor VIII.
Factor VIII is produced but is cleared rapidly because endogenous VWF cannot protect it effectively. - Type 2N VWD can resemble hemophilia A.
The inheritance pattern, VWF–factor VIII binding assay, and genetic testing may help distinguish the two. - A desmopressin trial must assess durability as well as peak response.
An impressive immediate increase in factor VIII does not guarantee sustained hemostatic protection. - Peridelivery treatment may require both factor VIII and functional VWF.
A concentrate containing both components can provide immediate factor VIII correction and donor VWF capable of stabilizing it. - Monitoring should follow the biological defect.
In type 2N VWD, factor VIII is often more informative than platelet-dependent VWF activity. - Successful delivery coverage does not eliminate delayed postpartum risk.
Replacement levels decline, pregnancy-associated hemostatic changes recede, and the underlying binding defect remains. - Postpartum hemorrhage requires integrated management.
Obstetric source control and disease-specific hemostatic therapy should proceed together.
Why This Case Matters
Type 2N VWD reveals a function of VWF that is easy to overlook.
VWF is not only a mediator of platelet adhesion. It is also the carrier that allows factor VIII to survive in the circulation.
In this patient, platelet-dependent VWF activity remained normal while factor VIII fell to levels more typical of hemophilia. The diagnosis became visible only when the relationship between the two proteins was examined.
The case also demonstrates that a treatment response has more than one dimension.
Desmopressin produced an excellent immediate factor VIII peak, but no one established how long that response lasted. Humate-P produced both a strong peak and sustained peridelivery protection, yet delayed postpartum bleeding still occurred after the initial period of coverage had passed.
The central lesson is therefore relational:
In type 2N VWD, the important question is not simply how much VWF or factor VIII is present, but whether VWF can protect factor VIII for as long as the clinical challenge requires.